Fig. 5: Antitumor effects of TPDA-TDTA-COF, TPDA-BT-COF, and TPDA-ViBT-COF in an MC38 tumor-bearing mice model.

a The treatment protocol of AIE COF-mediated antitumor effects. b The images and the weight of MC38 tumors on day 15 and presented as box plots showing median with whiskers at minimum and maximum values, n = 6 independent samples. P_{G(1 vs 6)} = 0.0008, P_{G(2 vs 6)} = 0.0001, P_{G(3 vs 6)} = 0.0004. c Tumor volume of MC38 tumor-bearing mice, n = 6 independent samples. P_{G(1 vs 6)} = 0.0003, P_{G(2 vs 6)} = 0.0004, P_{G(3 vs 6)} = 0.0007. d Body weights of MC38 tumor-bearing mice, n = 6 independent samples. e Quantification of T cell (CD3⁺) gating on CD45⁺ cells in tumor, n = 6 independent samples. P_{G(1 vs 6)} = 0.0002, P_{G(2 vs 6)} = 0.0004, P_{G(3 vs 6)} = 0.0012. f Quantification of CD4⁺ T_EM (CD44⁺CD62L⁻) in tumor, n = 6 independent samples. g Quantification of MDSC gating on CD11b⁺ MHCII⁻ cells in tumor, n = 6 independent samples. P_{G(1 vs 6)} = 1.42E-05, P_{G(2 vs 6)} = 5.72E-05, P_{G(3 vs 6)} = 1.44E-05. h Quantification of the gating of CD4⁺ T_CM (CD44⁺CD62L⁺) on CD3⁺ CD4⁺ in both TDLN, n = 6 independent samples. P_{G(1 vs 6)} = 0.0002, P_{G(2 vs 6)} = 0.0004. i Quantification the gating of CD8⁺ T_CM (CD44⁺CD62L⁺) on CD3⁺ CD8⁺ in TDLN, n = 6 independent samples. j Quantification the gating of CD4⁺ T_CM (CD44⁺CD62L⁺) on CD3⁺ CD4⁺ in spleen, n = 5 independent samples. k Quantification the gating of CD8⁺ T_CM (CD44⁺CD62L⁺) on CD3⁺ CD8⁺ in spleen, n = 5 independent samples. l Quantification of mDC in the TDLN, n = 6 independent samples. P_{G(1 vs 6)} = 9.19E-05. Data are presented as mean ± SEM and statistical significance was assessed using one-way ANOVA with post hoc Tukey test was used when comparing more than two groups. Source data are provided as a Source Data file.